AstraZeneca closed at $164.21, down 1.17% and underperforming a session in which the S&P 500 lost 0.17%, the Dow fell 0.26% and the Nasdaq slipped 0.09%. Ahead of its October 30, 2026 earnings release, the company is expected to post earnings per share of $2.17, an 8.82% decline from the year-earlier quarter, on revenue of $16.07 billion, up 5.82%. For the full year, the Zacks Consensus Estimates forecast earnings of $9.37 per share and revenue of $63.12 billion, changes of +2.29% and +7.45% respectively. Over the past 30 days the consensus EPS estimate has fallen 8.05%, and AstraZeneca currently carries a Zacks Rank of #3 (Hold). The stock trades at a forward P/E of 17.73 versus an industry average of 25.2, with a PEG ratio of 1.4 against the Medical - Biomedical and Genetics industry's 1.95.
AstraZeneca PLCQ4 earnings preview points to an 8.82% EPS decline and consensus EPS estimates have fallen 8.05% over 30 days.
